ERA-NET EuroNanoMed Allocates €8 Million to European Transnational Research Projects in Nanomedicine

- Eight projects from 10 countries were chosen to be funded as part of the 2nd call -

- The 3rd call will be launched in January 2011 -

SACLAY, France--(BUSINESS WIRE)-- EuroNanoMed, a European funding initiative under the ERA-Net scheme of the European Commission aimed at advancing transnational research in Nanomedicine, announced today the projects that will be funded following its 2nd joint transnational call for collaborative research projects. Eight projects, involving 46 partners from 10 countries will be funded with €8 Million provided by EuroNanoMed partners. The research projects were chosen from 33 applications involving 178 applicant groups from 19 EU member and associated states/regions.

The 2nd joint transnational call for proposals was launched by ERA-Net EuroNanoMed in March 2010 to promote collaborative and interdisciplinary research in Nanomedicine. The call focused on the three main subfields of Nanomedicine: diagnostics, targeted delivery systems and regenerative medicine. The applications were reviewed by external referees, taking into account the scientific, technical, clinical and commercial merit of the projects, followed by evaluation of an international peer review panel. The 8 funded projects encompass all three subfields of Nanomedicine covering diverse medical issues such as cancer, inflammatory diseases, bone regeneration, muscular dystrophy, immunology and vaccines.

Dr. Virginie Sivan, Coordinator and Chair of the Executive Board of ERA-Net EuroNanoMed said, "Nanomedicine is the medicine of the future. It has the potential of revolutionizing every aspect of health care, including diagnostics, imaging, drug delivery and sophisticated therapies. As evident by the excellent projects selected by ERA-Net EuroNanoMed, Europe is a central player in biological nano-research. I am convinced that the quality and diversity of the selected projects will help advance Nanomedicine research. The EuroNanoMed partners hope to get the support of the European Commission to be able to continue the successful work in the next years."

Following the first two successful Calls in 2009 and 2010, EuroNanoMed will launch a 3rd Joint Transnational Call for innovative research projects in Nanomedicine in January 2011.

About Nanomedicine

Nanomedicine is the application of nanotechnology to medicine and healthcare. The field takes advantage of the physical, chemical and biological properties of materials at the nanometer scale to be used for diagnosis, treatment and follow-up of diseases. Given the immense potential impact of Nanomedicine on public wellbeing and on economic growth, the field is of considerable strategic importance for Europe.

About ERA-Net EuroNanoMed

EuroNanoMed aims at leveraging European Nanomedicine through the support of transnational collaborative and multidisciplinary research and technology development projects with participants from academia, clinical/public health communities, and industry. The ERA-Net EuroNanoMed was created to bridge the gap between academic research and industrial and clinical applications, encouraging the participation of small and medium enterprises. The ERA-Net EuroNanoMed initiative comprises 24 partners from 18 European Member- and associated states/regions. Additional information is available at http://www.euronanomed.net

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6506124&lang=en



CONTACT:

EuroNanoMed Contact:
Dr. Virginie Sivan
Coordinator ERA-Net EuroNanoMed
+33 169-08-87-99
[email protected]
or
Dr. Olaf Rotthaus
Chair of EuroNanoMed Network Steering Committee
+49 211-6214-233
[email protected]
or
Media contact:
Tsipi Haitovsky
+972-52-598-9892
[email protected]

KEYWORDS:   Europe  France  Middle East  Israel

INDUSTRY KEYWORDS:   Technology  Nanotechnology  Health  Biotechnology  Clinical Trials  Oncology  Pharmaceutical  Other Health  Research  Science  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Barely two years after paying up $263 million for the ex-Asia rights to BeiGene’s tislelizumab, Celgene is bowing out—to the tune of $150 million.

A University of Pennsylvania team discovered that a protein called TOX helps determine the fate of exhausted T cells in cancer and other diseases.

AstraZeneca is set to spend $630 million on R&D in South Korea over the next five years as part of a wider cooperative agreement.